Tonix Pharmaceuticals to Showcase Rheumatology Advances at EULAR 2025
Tonix Pharmaceuticals to present at EULAR 2025, advancing rheumatologic treatments and fibromyalgia therapy TNX-102 SL, under FDA review. Read more.
This news highlights Tonix Pharmaceuticals' pivotal role in developing innovative treatments for fibromyalgia and other conditions, potentially improving the quality of life for millions. Their work on TNX-4200 also addresses critical national security needs by protecting military personnel from biological threats, showcasing the company's broad impact on both healthcare and defense sectors.